Last updated: May 11, 2026 · Reading time: 14 minutes
For the first time, Medicare is going to cover GLP-1 weight-loss drugs. Not for everyone, not forever, and not the way most insurance benefits work. But starting July 1, 2026, eligible Medicare beneficiaries will pay $50 a month for Wegovy, Zepbound, or Foundayo. That’s a drop of roughly $1,200 a month from the cash price of these drugs.
The program is called the Medicare GLP-1 Bridge. CMS announced it in December 2025 and extended it in May 2026 to run through December 31, 2027. It’s unusual in several ways. It sits outside Part D entirely. It uses a separate claims processor with its own billing codes. It doesn’t count toward your annual drug-cost cap. And it’s scheduled to end in 18 months, at which point nobody (including CMS) knows what replaces it.
This guide walks through everything that’s currently known: who qualifies, what it costs, which drugs are covered, how to actually get a prescription filled, and what happens when the program ends. We update it weekly through July 2026 as CMS releases operational details, then monthly after launch.
The 60-Second Summary
What it is: A short-term Medicare demonstration program providing GLP-1 weight-loss drugs for $50 per month.
When it runs: July 1, 2026 through December 31, 2027.
Who qualifies: Medicare Part D beneficiaries who fit one of three pathways: BMI of 35 or higher alone; BMI of 30-34.9 with a qualifying severe condition (HFpEF, uncontrolled hypertension on two medications, or chronic kidney disease stage 3a or higher); or BMI of 27-29.9 with a qualifying cardiovascular condition (prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease). Full criteria below.
What it costs: A flat $50 per month, regardless of the drug or dose.
Drugs covered: Wegovy (injection and pill), Zepbound (KwikPen formulation only), and Foundayo (pill).
How to enroll: No enrollment form. Your doctor submits a prior authorization to the CMS central processor. Once approved, your pharmacy bills the central processor directly and you pay $50 at the counter.
The catch: The $50 does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap. Beneficiaries who receive the Low-Income Subsidy (“Extra Help”) cannot use Extra Help for Bridge drugs.
What Is the Medicare GLP-1 Bridge?
Medicare has been statutorily barred from covering medications for weight loss since the Medicare Modernization Act of 2003. That restriction is the reason older Americans have paid cash prices of $149 to $699 a month for Wegovy and Zepbound, even when their private-insurance peers paid little or nothing.
The Bridge is the workaround. Rather than rewriting Part D coverage rules (a years-long process), CMS used its authority under Section 402 of the Social Security Amendments of 1967 to create a “demonstration project.” Demonstrations let the federal government test new approaches to Medicare payment outside the usual coverage framework. That legal mechanism is why the Bridge looks so different from the rest of Medicare Part D.
Here is how the money flows. Under the Bridge, participating manufacturers (Novo Nordisk and Eli Lilly) have agreed to provide the eligible drugs at a net price of $245 per monthly supply. The beneficiary pays $50 at the pharmacy counter. A central processor, separate from any Part D plan, reimburses the pharmacy at the wholesale acquisition cost minus the beneficiary’s $50, plus a dispensing fee. The manufacturer then pays CMS the difference between the wholesale cost and the agreed $245 net price.
If that sounds complicated, it is. The practical consequence for you is simpler: your Part D plan is not involved. Your plan does not approve, deny, or administer the benefit. The CMS central processor handles everything, using a dedicated Bank Identification Number (028918) and Processor Control Number (MEDDGLP1BR).
The Bridge was originally announced as a six-month pilot. In May 2026, CMS extended it through the end of 2027, giving the agency 18 months to gather utilization data before the planned BALANCE Model launches in Part D in 2028.
Who Qualifies for the Medicare GLP-1 Bridge?
Three things have to be true for you to qualify.
You have to be enrolled in Medicare Part D. That means either a standalone Prescription Drug Plan (PDP) or a Medicare Advantage plan that includes drug coverage. If you have Original Medicare without a Part D plan, you do not qualify, even if you meet every clinical criterion below. Dual-eligible beneficiaries (those with both Medicare and Medicaid) and those enrolled in certain Special Needs Plans are eligible.
You have to meet the clinical criteria. Per CMS guidance summarized by the AMCP, there are three eligibility pathways based on BMI and clinical condition. You qualify under any one of them:
- Pathway 1: BMI of 35 or higher, no other conditions required.
- Pathway 2: BMI of 30 to 34.9, with at least one of: heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension (above 140/90 on two antihypertensive medications), or chronic kidney disease stage 3a or higher.
- Pathway 3: BMI of 27 to 29.9, with at least one of: prediabetes per American Diabetes Association criteria, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
The specificity matters. General “hypertension” isn’t the criterion for pathway 2; it has to be uncontrolled despite two medications. General “kidney problems” doesn’t qualify; the CKD has to be staged at 3a or higher based on lab work. Obstructive sleep apnea, even when documented alongside obesity, doesn’t qualify for the Bridge. OSA is covered under standard Part D when Zepbound is prescribed for the OSA indication separately.
Your doctor has to write the prescription with a weight-management indication. This is where it gets subtle. If you take a GLP-1 for Type 2 diabetes, the Bridge does not apply to you. Your drug is covered under standard Part D rules, at whatever your plan negotiates. If you take Wegovy for cardiovascular risk reduction (its second FDA-approved use), same answer: Part D, not Bridge. The Bridge is specifically for the obesity indication.
That distinction creates an odd outcome. The same drug can cost two different amounts under Medicare depending on what your prescriber writes on the prior authorization. As the KFF Health News reporting notes, a Medicare beneficiary with both Type 2 diabetes and obesity may end up paying their Part D plan’s copay for the same prescription that a non-diabetic peer gets for $50.
If you are already on a GLP-1 for weight loss, you can still qualify even if your current BMI is below the eligibility threshold, provided you met the threshold when you started. Your prescriber attests on the prior authorization request that you met the BMI criteria at treatment initiation. This pathway matters: a Mizuho analyst estimate cited by CNN puts current oral-Wegovy users alone at around 400,000.
For the full eligibility deep-dive, see Medicare GLP-1 Bridge eligibility: BMI, comorbidities, and the prescriber-attestation pathway (coming soon).
What It Costs, and the Catch
The Bridge price is $50 per month. Flat. The same whether you are taking the 0.25 mg starter dose of Wegovy or the 17.2 mg maximum dose of Foundayo. The same in January as in December. The same whether you have hit your Part D deductible or not.
Here is the catch most coverage glosses over.
Because the Bridge operates outside the Part D benefit, none of the money you pay counts toward your Part D protections. The $50 monthly does not count toward your annual deductible. It does not count toward the $2,100 out-of-pocket cap in 2026 or the $2,400 cap in 2027. And it does not count toward your “true out-of-pocket” (TrOOP) costs under the standard Part D benefit phases.
For a beneficiary on multiple expensive prescriptions, that’s a meaningful loss of protection. You could spend $600 on Bridge drugs in a year and arrive at December still owing your full deductible on every other medication.
The second catch is sharper. Beneficiaries who receive the Low-Income Subsidy, commonly called Extra Help, can’t apply that subsidy to Bridge drugs. A senior who pays $1.55 or $4.50 for most prescriptions through Extra Help is still going to pay the full $50 for Wegovy under the Bridge. As KFF’s Juliette Cubanski told KFF Health News, $50 a month “is a lot of money for somebody who’s living on a $750-a-month Social Security check.”
Compared to cash prices, the Bridge is a substantial discount. Current retail prices for GLP-1 weight-loss drugs run between $149 and $699 a month. Compared to Part D coverage for a diabetic indication, it can be either better or worse depending on the plan. For full cost mechanics, see the cost breakdown (coming soon).
Which GLP-1 Drugs Are Covered?
Three drugs, with one important formulation restriction.
Wegovy (semaglutide). Made by Novo Nordisk. All formulations and all doses are covered, including both the injectable pen and the oral pill. Wegovy is the only Bridge drug with an FDA-approved indication for reducing the risk of major cardiovascular events in adults with obesity and known heart disease. According to Novo Nordisk’s announcement, all doses of both the injection and the pill are available under the Bridge.
Zepbound (tirzepatide). Made by Eli Lilly. Only the KwikPen formulation is covered under the Bridge, not the vial-and-syringe version. This is the easiest thing to get wrong, including for pharmacists who are not yet familiar with the program. If you are switching to Zepbound under the Bridge, ask your prescriber to specifically write for the KwikPen.
Foundayo (orforglipron). Made by Eli Lilly. FDA-approved on April 1, 2026 under the Commissioner’s National Priority Voucher pilot program, making it the fastest approval of a new molecular entity since 2002. Foundayo is a once-daily pill with no food or water restrictions, which distinguishes it from the Wegovy pill (which has to be taken on an empty stomach 30 minutes before food or drink). In the ATTAIN-1 trial, the highest dose produced an average weight loss of 27.3 pounds over 72 weeks, compared to 2.2 pounds with placebo.
What is not covered under the Bridge: Ozempic, Mounjaro, Rybelsus, compounded GLP-1s from compounding pharmacies, and any GLP-1 not listed above. Ozempic and Mounjaro are approved for Type 2 diabetes, not obesity, so they remain under standard Part D coverage. Compounded semaglutide and tirzepatide, the versions that have proliferated through telehealth platforms during shortages, are not part of the manufacturer agreements with CMS and will not be reimbursed.
When comparing the three covered drugs, the choice usually comes down to dosing format (pill vs. injection), tolerance to side effects, and prescriber preference. For a head-to-head comparison, see Wegovy vs. Zepbound vs. Foundayo: which to ask your doctor about (coming soon).
How to Enroll: Step-by-Step
There is no enrollment form for the Bridge. You do not sign up. You do not pick a plan. The process runs through your existing doctor and pharmacy.
Step 1: Confirm you have Medicare Part D. Check your Medicare card and your insurance documents. If you have only Original Medicare (Parts A and B) without a standalone PDP or a Medicare Advantage drug plan, you need to enroll in Part D first. Outside the Annual Enrollment Period (October 15 through December 7), you can only enroll if you qualify for a Special Enrollment Period.
Step 2: Talk to your doctor. Bring your full medical history, current weight, and any prior weight-loss attempts. Your doctor will assess whether you meet the BMI and comorbidity criteria, and which of the three covered drugs is the best fit. If you have Type 2 diabetes, ask explicitly whether you are being prescribed for the obesity indication (Bridge) or the diabetes indication (Part D). The answer affects what you pay.
Step 3: Your doctor submits a prior authorization to the CMS central processor. This is the part that confuses pharmacists, prescribers, and Part D plan staff. Prior auth requests for Bridge drugs do not go to your Part D plan. They go to the central processor that CMS contracts to administer the demonstration. According to CMS guidance, if a provider mistakenly submits a Bridge prior auth to a Part D plan, the plan is supposed to redirect them to the central processor.
Step 4: Once approved, fill at your pharmacy. The pharmacist bills the central processor using dedicated billing codes: Bank Identification Number 028918 and Processor Control Number MEDDGLP1BR. If your pharmacist has not yet been briefed on the Bridge process (likely in the early weeks of July 2026), it may help to bring a printed copy of the CMS guidance.
Step 5: Pay $50 at the counter. No paperwork, no reimbursement claims, no waiting on your plan.
For what to do if you are denied, see Medicare GLP-1 Bridge denials and appeals (coming soon).
What Happens After December 31, 2027?
We don’t know. Neither does CMS, with full confidence.
The Bridge is paired with a longer-term initiative called the BALANCE Model, which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. BALANCE is supposed to bring GLP-1 coverage into Part D itself starting in 2028. Under it, the cost would shift from the federal government back to Part D insurers, and from Part D insurers back to beneficiaries through premiums and cost-sharing.
The math gets uncomfortable. One actuarial analysis cited in KFF’s reporting found that BALANCE could cost insurers billions of dollars in its first year. Whether the $50 price point survives into the BALANCE era is an open question. Part D plans have substantial discretion over formulary placement, prior authorization, and step therapy. The same drug that costs $50 under the Bridge could plausibly cost a $200 copay under a Part D plan two years later.
There’s also a clinical question. As KFF Health News reported, most patients who stop taking GLP-1s regain the weight they lost. If the price spikes when the Bridge ends, beneficiaries may face a choice between paying out of pocket and reversing their treatment gains.
Our honest read: build the next 18 months around what works at $50, but plan for the price to change. If you start a GLP-1 under the Bridge in July 2026, you have 18 months of predictable cost. After that, the assumption set has to be rebuilt.
Frequently Asked Questions
Can I switch between Wegovy, Zepbound, and Foundayo under the Bridge?
Yes, with a new prescription and a new prior authorization. There is no penalty for switching, but the central processor will need an updated PA each time the drug changes.
What if I have Medicare Advantage instead of Original Medicare?
You qualify, as long as your Medicare Advantage plan includes Part D drug coverage. The Bridge operates nationwide regardless of plan type. Your Part D coverage source (standalone PDP or MA-PD) is not what determines access.
Does the Bridge cover compounded GLP-1s from telehealth services?
No. The Bridge only covers the three FDA-approved drugs (Wegovy, Zepbound KwikPen, and Foundayo) from their named manufacturers. Compounded semaglutide and tirzepatide that proliferated during the 2023-2025 shortages are not part of the demonstration.
I have Type 2 diabetes. Does the Bridge cover my GLP-1?
Not for the diabetes indication. If your prescription is written for Type 2 diabetes, it is covered under standard Part D rules at whatever copay your plan applies. If you have both Type 2 diabetes and obesity meeting the Bridge criteria, your prescriber decides which indication to use on the prior authorization, and that choice determines whether you pay the Part D copay or the $50 Bridge price.
What if my doctor hasn’t heard of the Bridge yet?
That’s likely, especially in the first weeks after July 1, 2026. The most useful thing you can do is print the CMS Medicare GLP-1 Bridge guidance page and bring it to your appointment. Your doctor’s billing staff will also need the central-processor information (BIN 028918, PCN MEDDGLP1BR).
Can I appeal a denial?
Yes. The Bridge does not eliminate normal Part D appeal rights, and the central processor handles denials and appeals through CMS-defined procedures. Operational details on the appeals process were still being finalized as of CMS guidance issued in March 2026.
Is the $50 price guaranteed for the full 18 months?
Yes, for the duration of the demonstration. The $50 copay is fixed regardless of dosage increases or drug changes. What happens after December 31, 2027 is uncertain.
Will my local pharmacy know how to process the Bridge?
Eventually. CMS has said pharmacies do not need to opt in, and the agency is conducting outreach and education ahead of launch. Expect some confusion in July and August 2026 as pharmacies adapt to the new BIN/PCN routing.
Sources and References
- Medicare GLP-1 Bridge — CMS official program page
- CMS announcement: Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications
- What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid — KFF (updated May 11, 2026)
- Regulatory NewsBREAK: CMS Releases FAQs on the Medicare GLP-1 Bridge — AMCP (March 2026)
- A New Medicare Option for Weight Loss Drugs — KFF Health News
- Wegovy Access Expanded for Medicare Beneficiaries — Novo Nordisk press release (May 7, 2026)
- FDA Approves Lilly’s Foundayo (orforglipron) — Eli Lilly press release (April 1, 2026)
- FDA Approves First New Molecular Entity Under National Priority Voucher Program — FDA (April 1, 2026)
- Medicare to launch weight loss drug option in July with $50 copay — NPR
This guide is for informational purposes only and is not medical advice. Eligibility decisions, prescribing decisions, and clinical recommendations should be made between you and a licensed healthcare provider. Weight Loss RX Guide is not affiliated with CMS, Medicare, Eli Lilly, or Novo Nordisk. We may receive compensation when readers connect with services through links on this site; see our affiliate disclosure for details.